Takeda Pharmaceutical Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Takeda Pharmaceutical Limited (TAK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Takeda Pharmaceutical Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 30,079M vs 807,292M combined for its competitors (3.6% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+288.1% annualized vs trailing 12 months), vs decelerating (-33.9%) for its tracked peer group.
- Growth: Takeda Pharmaceutical Limited generated 0.1% revenue growth year over year in Q4 2025, vs 3.6% for its competitors combined.
- Profitability: Its 2.4% net margin compares with 20.4% for the peer group.
- Scale: Takeda Pharmaceutical Limited ranks #19 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.6% of industry market cap.
- Peer revenue share: Takeda Pharmaceutical Limited accounted for 17.9% of combined revenue among its tracked peer group, down from 18.5% a year earlier.
- Peer differentiation: Revenue per employee of $0.64M compares with $0.94M for the peer group (0.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
TAK Sales vs. its Competitors, Q4 2025
Takeda Pharmaceutical Limited reported revenue growth of 0.06 % year on year in Q4 2025, below its competitors' combined revenue growth of 3.62 %.
With a net margin of 2.36 %, Takeda Pharmaceutical Limited reported lower profitability than its competitors (20.43 %).
Takeda Pharmaceutical Limited generated 17.94 % of the combined sales of its peer group, down from 18.46 % a year earlier.
API endpoints for this dataset
Takeda Pharmaceutical Limited vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Takeda Pharmaceutical Limited reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Takeda Pharmaceutical Limited and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Takeda Pharmaceutical Company Limited | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (44) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Takeda Pharmaceutical Limited's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 0.1% for Takeda Pharmaceutical Limited. Takeda Pharmaceutical Limited's share of combined industry revenue moved from 6.07% to 5.58%, a loss of 0.49 percentage points.
Takeda Pharmaceutical Limited's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited | Yes | Yes | No | No |
| Competitors combined (152) | ||||
| High-Confidence Competitors (53) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 75.00 % (6 of 8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) | 12.50 % (1 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
TAK Stock Performance relative to its Competitors
TAK Stock Performance relative to High-Confidence Competitors
TAK Stock Performance relative to Similar-Size Competitors
TAK Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Chimerix Inc | 282.9% | Outperformed |
| 2 | Gt Biopharma Inc | 282.9% | Outperformed |
| 3 | Immunitybio inc | 282.9% | Outperformed |
| 4 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 5 | An2 Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Takeda Pharmaceutical Limited's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Takeda Pharmaceutical Limited's Comment on Competition and Industry Peers
Publicly Traded Peers of Takeda Pharmaceutical Company Limited
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Takeda Pharmaceutical Company Limited |
33,743.89 | 30,079.37 |
 Eli Lilly And Company |
1,209,663.60 | 86,462.00 |
 Johnson and Johnson |
676,352.29 | 99,335.00 |
 Beone Medicines Ltd |
612,622.08 | 6,128.24 |
 Abbvie Inc |
516,201.32 | 66,014.00 |
 Merck and Co Inc |
362,398.40 | 66,569.00 |
| SUBTOTAL | 5,547,053.76 | 837,868.88 |
Sign in to see all competitors of Takeda Pharmaceutical Company Limited.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Takeda Pharmaceutical Company Limited versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Takeda Pharmaceutical Limited's Competitors Named by the Company
Competitive relationships identified from Takeda Pharmaceutical Limited reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Passage Bio Inc | Company report | 85% |
| Morphic Holding inc | Company report | 85% |
| Larimar Therapeutics Inc | Company report | 85% |
| Nabla Bio | Company report | 85% |
| Curanex Pharmaceuticals Inc | Company report | 85% |
| Shattuck Labs Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Protalix Biotherapeutics inc | Company report | 85% |
| Ironwood Pharmaceuticals inc | Company report | 85% |
| Kamada Ltd | Company report | 85% |
| Acumen Pharmaceuticals Inc | Company report | 85% |
| Can fite Biopharma Ltd | Company report | 85% |
| Cytomx Therapeutics Inc | Company report | 85% |
| Adma Biologics Inc | Company report | 85% |
| Intellia Therapeutics Inc | Company report | 85% |
| Centessa Pharmaceuticals Plc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Abivax Sa | Company report | 85% |
| Celcuity Inc | Company report | 85% |
| INVO | Company report | 85% |
| NAYA | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Invo Fertility Inc | Company report | 85% |
| Ladrx Corporation | Company report | 85% |
| Neurosense Therapeutics Ltd | Company report | 85% |
| Cell Source Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| Nascent Biotech Inc | Company report | 85% |
| Igm Biosciences Inc | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Lava Therapeutics Nv | Company report | 85% |
| Centogene N v | Company report | 85% |
| Gri Bio Inc | Company report | 85% |
| Astria Therapeutics Inc | Company report | 85% |
| Spyre Therapeutics Inc | Company report | 85% |
| Protagonist Therapeutics inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Mersana Therapeutics inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Puma Biotechnology Inc | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Surrozen Inc | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| Adaptimmune Therapeutics Plc | Company report | 85% |
| Molecular Templates Inc | Company report | 85% |
| Bridgebio Pharma Inc | Company report | 85% |
| Voyager Therapeutics Inc | Company report | 85% |
| Arena Pharmaceuticals Inc | Company report | 85% |
| Vanda Pharmaceuticals Inc | Company report | 85% |
| Uniqure N v | Company report | 85% |
| Shire | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Jaguar Health Inc | Company report | 85% |
| Biocardia Inc | Company report | 85% |
| Vistagen Therapeutics Inc | Company report | 85% |
| Senti Biosciences Holdings Inc | Company report | 85% |
| Werewolf Therapeutics Inc | Company report | 85% |
| Canton Strategic Holdings Inc | Company report | 85% |
| Immunitybio inc | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Gilead Sciences Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Organon and Co | Company report | 85% |
| Sanofi | Company report | 85% |
| Nkarta Inc | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
| Myovant Sciences Ltd | Company report | 85% |
| Affimed N v | Company report | 85% |
| Cerus Corporation | Company report | 85% |
| Bolt Biotherapeutics Inc | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Viatris Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Vertex Pharmaceuticals Inc | Company report | 85% |
| Bellicum Pharmaceuticals Inc | Company report | 85% |
| Galapagos Nv | Company report | 85% |
| Prometheus Biosciences Inc | Company report | 85% |
| Tiziana Life Sciences Ltd | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Fortress Biotech Inc | Company report | 85% |
| Jazz Pharmaceuticals Plc | Company report | 85% |
| Nektar Therapeutics | Company report | 85% |
| Arcus Biosciences Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Humanigen Inc | Company report | 85% |
| Lexicon Pharmaceuticals Inc | Company report | 85% |
| United Therapeutics Corporation | Company report | 85% |
| Astrazeneca Plc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Takeda Pharmaceutical Limited's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Takeda Pharmaceutical Limited's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 16.79 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Takeda Pharmaceutical Company Limited.
Takeda Pharmaceutical Limited's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Takeda Pharmaceutical Company Limited | 33,744 | 639,986 | 15,106 |
| Eli Lilly And Company | 1,209,664 | 1,729,240 | 551,594 |
| Johnson and Johnson | 676,352 | 705,504 | 114,311 |
| Beone Medicines Ltd | 612,622 | 510,686 | 54,642 |
| Abbvie Inc | 516,201 | 1,158,140 | 181,509 |
| Merck and Co Inc | 362,398 | 887,587 | 42,267 |
| PEERS TOTAL | 5,513,310 | 938,723 | 138,914 |
Sign in to see all peers for Takeda Pharmaceutical Company Limited.
Takeda Pharmaceutical Limited's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 54.39 % |
| Merck and Co Inc | EMEA 21.50 % |
| Gilead Sciences Inc | United States 76.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Takeda Pharmaceutical Company Limited.
Takeda Pharmaceutical Limited's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Takeda Pharmaceutical Limited's industry classification, broader than the peer set above. Market cap in millions of $.Takeda Pharmaceutical Limited ranks #19 of 495 companies by market capitalization in its industry, holding 0.57 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 875, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,210,070 | 20.69 % |
| 2 | Johnson and Johnson | 674,004 | 11.53 % |
| 3 | Beone Medicines Ltd | 612,622 | 10.48 % |
| 4 | Abbvie Inc | 515,910 | 8.82 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 19 | Takeda Pharmaceutical Company Limited | 33,219 | 0.57 % |
Market cap and industry share for the rest of Takeda Pharmaceutical Limited's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Takeda Pharmaceutical Limited's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 14 | Gsk Plc | 102,777 | 5.88 % |
| 15 | Regeneron Pharmaceuticals Inc | 95,861 | 39.96 % |
| 16 | Teva Pharmaceutical Industries Limited | 49,428 | 69.86 % |
| 17 | Royalty Pharma Plc | 37,479 | 65.54 % |
| 18 | Spyre Therapeutics Inc | 1,234 | 12.3% |
| 19 | Takeda Pharmaceutical Company Limited | 33,219 | 53.20 % |
| 20 | Zoetis Inc | 1,234 | 12.3% |
| 21 | Zai Lab Limited | 1,234 | 12.3% |
| 22 | Roivant Sciences Ltd | 1,234 | 12.3% |
| 23 | United Therapeutics Corporation | 1,234 | 12.3% |
| 24 | Insmed Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Takeda Pharmaceutical Limited's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Takeda Pharmaceutical Limited's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 63.56 % | 37.99 % (avg) | +25.6 pp |
| Operating Margin | 7.48 % | industry median | +51.0 pp |
| EBITDA Margin | 3.82 % | -6.20 % (avg) | +10.0 pp |
| Capital Intensity (Capex / Revenue) | 4.38 % | 7.59 % (avg) | -3.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Takeda Pharmaceutical Limited's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 0.2x | 26.6x | -26.4x |
| EV / EBITDA | - | 15.9x | - |
| P/B | - | 4.3x | - |
| Return on Equity | 1.53 % | industry aggregate | -13.66 % |
| Return on Invested Capital | 1.89 % | -9.82 % (avg) | 11.71 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Takeda Pharmaceutical Limited's Strategic Group Map
Takeda Pharmaceutical Limited is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Takeda Pharmaceutical Limited's trailing-12-month revenue growth of 1.8% and operating margin of 7.5% compares with an average of 2.3% growth and 6.1% margin across its 8 closest peers by combined growth, margin and ROIC -- Takeda Pharmaceutical Limited sits below that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Takeda Pharmaceutical Limited's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Takeda Pharmaceutical Limited falls in the Dog quadrant: relative market share of 0.03x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Takeda Pharmaceutical Limited's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 875 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 4.38 % vs industry average 7.59 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Takeda Pharmaceutical Limited's dedicated Suppliers and Customers pages, not here.
Takeda Pharmaceutical Limited's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Takeda Pharmaceutical Limited falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Takeda Pharmaceutical Limited's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 51.0 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+288.1% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 13.7 points below the industry aggregate.
- Low relative market share vs the industry leader (0.03x).
Opportunities
- Trades at a lower P/E than the industry average (0.2x vs 26.6x) despite a higher return on invested capital -- a possible re-rating opportunity.
- A meaningful share of competitors (47.90 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-33.9% annualized).
Methodology: see Methodology: SWOT Analysis.
Takeda Pharmaceutical Limited's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Takeda Pharmaceutical Company Limited | 0.15 | 1.01 | 0.58 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
Sign in to see all peers for Takeda Pharmaceutical Company Limited.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Takeda Pharmaceutical Limited's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Takeda Pharmaceutical Company Limited | Q1 2025 | +1.8 % | -28.9 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| PEERS TOTAL | +10.3 % | +1.9 % |
Sign in to see all peers for Takeda Pharmaceutical Company Limited.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Takeda Pharmaceutical Limited's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Takeda Pharmaceutical Company Limited | Q1 2025 | -8.7 % | +8.5 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
Sign in to see all peers for Takeda Pharmaceutical Company Limited.
Takeda Pharmaceutical Limited's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Takeda Pharmaceutical Company Limited | 0.75% | 0.97% | 1.53% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
Sign in to see all peers for Takeda Pharmaceutical Company Limited.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Takeda Pharmaceutical Limited's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Takeda Pharmaceutical Company Limited | 0.31 | 1.12 |
| Eli Lilly And Company | 43.96 | 13.99 |
| Johnson and Johnson | 41.79 | 6.81 |
| Beone Medicines Ltd | 924.91 | 99.97 |
| Abbvie Inc | 50.14 | 7.82 |
| Merck and Co Inc | 118.32 | 5.44 |
| PEERS AVERAGE | 46.13 | 6.62 |
Sign in to see all peers for Takeda Pharmaceutical Company Limited.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.